Literature DB >> 19542256

Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure.

Jeffrey A Kline1, Michael T Steuerwald2, Michael R Marchick2, Jackeline Hernandez-Nino2, Geoffrey A Rose3.   

Abstract

BACKGROUND: No published data have systematically documented pulmonary artery pressure over an intermediate time period after submassive pulmonary embolism (PE). The aim of this work was to document the rate of pulmonary hypertension, as assessed noninvasively by estimated right ventricular systolic pressure (RVSP) of >or= 40 mm Hg 6 months after the diagnosis of submassive PE.
METHODS: We enrolled 200 normotensive patients with CT angiography-proven PE and a baseline echocardiogram to estimate RVSP. All patients received therapy with unfractionated heparin initially, but 21 patients later received alteplase in response to circulatory shock or respiratory failure. Patients returned at 6 months for repeat RVSP measurement, and assessments of the New York Heart Association (NYHA) score and 6-min walk distance (6MWD).
RESULTS: Six months after receiving a diagnosis, 162 of 180 survivors (90%) returned for follow-up, including 144 patients who had been treated with heparin (heparin-only group) and 18 patients who had been treated with heparin plus alteplase (heparin-plus-alteplase group). Among the heparin-only patients, the RVSP at diagnosis was >or= 40 mm Hg in 50 of 144 patients (35%; 95% CI, 27% to 43%), compared with 10 of 144 patients at follow-up (7%; 95% CI, 3% to 12%). However, the RVSP at follow-up was higher than the baseline RVSP in 39 of 144 patients (27%; 95% CI, 9% to 35%), and 18 of these 39 patients had a NYHA score of >or= 3 or exercise intolerance (6MWD, < 330 m). Among heparin-plus-alteplase patients, the RVSP was >or= 40 mm Hg in 11 of 18 patients at diagnosis (61%; 95% CI, 36% to 83%), compared with 2 of 18 patients at follow-up (11%; 95% CI, 1% to 35%). The RVSP at follow-up was not higher than at the time of diagnosis in any of the heparin-plus-alteplase patients (95% CI, 0% to 18%).
CONCLUSIONS: Six months after experiencing submassive PE, a significant proportion of patients had echocardiographic and functional evidence of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542256      PMCID: PMC2818852          DOI: 10.1378/chest.08-2988

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

1.  Long-term benefit of thrombolytic therapy in patients with pulmonary embolism.

Authors:  G V Sharma; E D Folland; K M McIntyre; A A Sasahara
Journal:  Vasc Med       Date:  2000       Impact factor: 3.239

2.  Thrombolytic therapy of pulmonary embolism: a meta-analysis.

Authors:  Gabriel Thabut; Dominique Thabut; Robert P Myers; Brigitte Bernard-Chabert; Rolana Marrash-Chahla; Hervé Mal; Michel Fournier
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

3.  Persistent post-embolic pulmonary hypertension.

Authors:  N D De Soyza; M L Murphy
Journal:  Chest       Date:  1972-12       Impact factor: 9.410

4.  Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism.

Authors:  F Schwarz; H Stehr; R Zimmermann; J Manthey; W Kübler
Journal:  Circulation       Date:  1985-01       Impact factor: 29.690

5.  Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects.

Authors:  B M McQuillan; M H Picard; M Leavitt; A E Weyman
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

6.  Long-term prognosis of treated acute massive pulmonary embolism.

Authors:  R J Hall; G C Sutton; I H Kerr
Journal:  Br Heart J       Date:  1977-10

7.  Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data.

Authors:  M Riedel; V Stanek; J Widimsky; I Prerovsky
Journal:  Chest       Date:  1982-02       Impact factor: 9.410

8.  Randomized, controlled trial of immediate versus delayed goal-directed ultrasound to identify the cause of nontraumatic hypotension in emergency department patients.

Authors:  Alan E Jones; Vivek S Tayal; D Matthew Sullivan; Jeffrey A Kline
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

Review 9.  Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.

Authors:  Marije ten Wolde; Maaike Söhne; Elske Quak; Melvin R Mac Gillavry; Harry R Büller
Journal:  Arch Intern Med       Date:  2004 Aug 9-23

10.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.

Authors:  Vittorio Pengo; Anthonie W A Lensing; Martin H Prins; Antonio Marchiori; Bruce L Davidson; Francesca Tiozzo; Paolo Albanese; Alessandra Biasiolo; Cinzia Pegoraro; Sabino Iliceto; Paolo Prandoni
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  40 in total

Review 1.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Pulmonary Embolism: The Astute Interventional Radiology Clinician.

Authors:  Akhilesh K Sista
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Bilateral total knee arthroplasty: risk factors for major morbidity and mortality.

Authors:  Stavros G Memtsoudis; Yan Ma; Ya-Lin Chiu; Lazaros Poultsides; Alejandro Gonzalez Della Valle; Madhu Mazumdar
Journal:  Anesth Analg       Date:  2011-07-13       Impact factor: 5.108

5.  Initial thrombolysis treatment compared with anticoagulation for acute intermediate-risk pulmonary embolism: a meta-analysis.

Authors:  Qixia Xu; Ke Huang; Zhenguo Zhai; Yuanhua Yang; Jun Wang; Chen Wang
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

6.  High Prevalence of Persistent Breathlessness Following Sub-Massive Pulmonary Embolism in Patients Presenting to a Large Regional Hospital in South Wales.

Authors:  Patrick Flood-Page
Journal:  Turk Thorac J       Date:  2020-11-01

7.  Management of pulmonary embolism with rheolytic thrombectomy.

Authors:  Lisa Ferrigno; Robert Bloch; Judson Threlkeld; Thomas Demlow; Raman Kansal; Riyad Karmy-Jones
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 8.  How I use catheter-directed interventional therapy to treat patients with venous thromboembolism.

Authors:  Suresh Vedantham; Akhilesh K Sista
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

9.  Thrombolysis in submassive pulmonary embolism, prudent or puerile?

Authors:  Aamer Rehman; Shafaq Yousaf; Atul Chugh
Journal:  BMJ Case Rep       Date:  2013-01-24

10.  Leukocyte expression of heme oxygenase-1 [hmox1] varies inversely with severity of tricuspid regurgitation in acute pulmonary embolism.

Authors:  Jeffrey A Kline; Nury M Steuerwald; John A Watts; Mark Courtney; Herbert L Bonkovsky
Journal:  Thromb Res       Date:  2015-08-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.